Farmacéuticas.
06 de septiembre de 2018
bioLIVE bio processing and manufacturing league table ranks US top and China bottom despite bio boom
Amsterdam, 6 September 2018: bioLIVE – the new bioprocessing and manufacturing event running alongside this year’s CPhI Worldwide – today announces the initial findings of the world’s first ever biopharma league table, which evaluates the reputations of major bio manufacturing countries across a number of characteristics (scored 1-10). This follows the launch of the small molecule pharma league table introduced last year.
Acceder
Farmacéuticas.
23 de agosto de 2018
CPhI Annual Report expert warns ‘innovation is being hindered by regulators’
Amsterdam, 23rd August 2018: CPhI Worldwide the world’s largest pharma event – taking place in Madrid October (9-11) and organized by UBM (part of Informa plc) – releases the first part of its 6th Annual Report with a stark warning from Girish Malhotra, President of EPCOT International, that regulators are holding back the industry’s ability to innovate.
Acceder
Farmacéuticas.
15 de agosto de 2018
Middle East and Africa pharma economy to reach US$38.8bn by 2021
Amsterdam, 15th August 2018: CPhI MEA (Middle East and Africa) launches next month as favourable market conditions are driving increased growth across the Middle East and North Africa (MENA) pharma market – ageing and gentrifying populations, increased healthcare spending, and a modernising supply chain are transforming prospects in the region.
Acceder
Farmacéuticas.
01 de agosto de 2018
WuXi STA’s Jinshan Site Passes Fourth U.S. FDA Inspection
SHANGHAI, August 1, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its Active Pharmaceutical Ingredient (API) manufacturing facility at Jinshan (Shanghai, China) has successfully passed its fourth inspection from the U.S. Food and Drug Administration (USFDA) – with no Form 483s issued. The site previously passed three FDA inspections in 2013, 2014 and 2016.
Acceder
Farmacéuticas.
20 de julio de 2018
WuXi STA and Antengene Sign Development and Manufacturing Agreement
SHANGHAI, 20 July 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a biopharmaceutical company, recently announced a strategic partnership for the CMC development and manufacturing of innovative oncology drugs. Under the terms of the collaboration, WuXi STA will provide Antengene an integrated solution in process R&D and manufacturing, using the MAH scheme to accelerate new drug development.
Acceder